NCT04706949Unknown2 期
A Prospective, Single Center, Single Arm, Phase II Clinical Trial of Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment of Patients With HER2 Mutant or Amplified Recurrent / Metastatic Non-small Cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
A prospective, single center, single arm, phase II clinical trial of Pyrotinib combined with pemetrexed plus carboplatin in the first-line treatment of patients with HER2 mutant or amplified recurrent / metastatic non-small cell lung cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged≥18 and <75 years.
- •Histologically or cytologic confirmed Non-small cell lung cancer, Phase IIIB or IV according to UICC
- •ECOG performance status of 0 to
- •Life expectancy of more than 3 months.
- •Confirmed HER2 mutation and amplification by Central Laboratory. Direct sequencing (RT-PCR or ARMS-PCR) or second generation sequencing (NGS) was used for HER2 mutation, and fluorescence in situ hybridization (FISH) or ngs was used for HER2 amplification;
- •At least one RECIST 1.1 defined measurable lesions.
- •Patients who had not received systemic treatment for advanced / metastatic NSCLC in the past but had disease progression more than 12 months after receiving neoadjuvant therapy or the last use of adjuvant therapy could be enrolled.
- •Required laboratory values including following parameters:ANC≥1.5×109/L,Platelet count≥90×109/L,Hemoglobin≥90 g/L;Total bilirubin:≤ 1.5×upper limit of normal, ULN, ALT and AST≤ 2.0×ULN; BUN and Cr: ≤1.5 x ULN;creatine clearance rate: ≥ 50 mL/min, LVEF: ≥ 50%; QTcF:< 470 ms for female and < 450 ms for male.
- •Signed informed consent.
排除标准
- •Previous therapy with other HER2 inhibitors.
- •Inability to swallow、chronic diarrhea and intestinal obstruction that affect the drug taking and absorption.
- •There is unstable third space effusion (such as large amount of pleural effusion and ascites).
- •Received radiotherapy, chemotherapy, surgery or other targeted therapy for non-small cell lung adenocarcinoma within 4 weeks before taking the study drug for the first time.
- •Persistence of clinically relevant therapy related toxicities from previous therapy (greater than Common Terminology Criteria for Adverse Event(CTCAE) 4.0 grade 1).
- •Patients with active brain metastasis (without medical control), cancerous meningitis, spinal cord compression, or diseases of brain or pia mater found by CT or MRI examination during screening (patients with brain metastasis who had completed treatment or stable symptoms within 28 days before taking the study drug for the first time can be enrolled, but they need to be confirmed as having no symptoms of cerebral hemorrhage by MRI, CT or venography evaluation).
- •Participated in other drug clinical trials within the past 4 weeks before start of therapy.
- •Other malignant tumors in the past 5 years, excluding cervical carcinoma in situ, basal cell carcinoma of skin or squamous cell carcinoma of skin.
- •At the same time receive any other anti-tumor treatment, such as immune agents and anti angiogenesis inhibitors.
- •Those with allergic constitution or known allergic history to the drug components of the scheme.
- •Active infection(judged by the researcher).
- •Subjects had any heart disease, including: (1) angina; (2) requiring medication or clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5) Any heart diseases judged by investigator as unsuitable to participate in the trial.
- •Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test.
- •According to the judgment of the researchers, there are concomitant diseases (such as uncontrolled hypertension, diabetes, thyroid disease, etc.) that seriously endanger the safety of patients or affect the completion of the study.
- •Known history of neurological or psychiatric disease, including epilepsy or dementia.
- •Any of the other conditions of which researchers believe that the patient is not fit to take part in the study.
研究组 & 干预措施
Pyrotinib combined with pemetrexed plus carboplatin
Experimental
干预措施: Pyrotinib combined with pemetrexed plus carboplatin (Drug)
结局指标
主要结局
PFS
时间窗: from the first cycle of treatment (day one) to two month after the last cycle (each cycle is 21 days)]
progression free survival
次要结局
未报告次要终点
研究者
Jialei Wang
Principal Investigator
Fudan University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast CancerHER2-positive Advanced Breast CancerNCT04903652Tianjin Medical University Cancer Institute and Hospital30
Unknown
2 期
Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast CancerMetastatic Breast CancerNCT04407988Hunan Cancer Hospital86
招募中
2 期
Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung CancerNon-small Cell Lung CancerNCT05751018Peking Union Medical College Hospital18
进行中（未招募）
2 期
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast CancerHormone-receptor Positive Breast CancerBreast CancerNCT04872985Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University140
Unknown
2 期
Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast CancerPyrotinibBreast DiseasesVinorelbineBreast CancerHER2-positive Breast CancerNCT04605575Sun Yat-sen University208